Skip to main content
PMC home page
The Western Journal of Medicine logoLink to The Western Journal of Medicine
. 1990 Jul;153(1):50–61.

Pathophysiology and management of endometrial hyperplasia and carcinoma.

Y S Fu 1, J C Gambone 1, J S Berek 1
PMCID: PMC1002466  PMID: 2202159

Abstract

Endometrial cancer is currently the commonest pelvic malignancy affecting American women, most of whom share the same pathophysiologic basis, that is, unopposed estrogenic stimulation. The initial result of hyperestrogenism is the development of endometrial hyperplasia, which is reversible in most cases by appropriate hormonal therapy. Persistent stimulation eventually leads to atypical hyperplasia with nuclear atypia and invasive carcinoma. Because there is no cost-effective screening method for the detection of endometrial hyperplasia and carcinoma, it is essential to survey the high-risk population with appropriate diagnostic techniques. After diagnosis, therapy should be individualized based on pathologic findings (cell type and histologic grade) and extent of disease (International Federation of Gynaecologists and Obstetricians stage, depth of myometrial invasion, and pelvic and para-aortic lymph node status). Recent studies suggest that sex hormone receptors and nuclear DNA ploidy patterns provide useful prognostic information independent of histologic grade.

Full text

PDF
50

Images in this article

52Image
on p.52

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aalders J. G., Abeler V., Kolstad P. Clinical (stage III) as compared to subclinical intrapelvic extrauterine tumor spread in endometrial carcinoma: a clinical and histopathological study of 175 patients. Gynecol Oncol. 1984 Jan;17(1):64–74. doi: 10.1016/0090-8258(84)90061-1. [DOI] [PubMed] [Google Scholar]
  2. Aalders J. G., Abeler V., Kolstad P. Recurrent adenocarcinoma of the endometrium: a clinical and histopathological study of 379 patients. Gynecol Oncol. 1984 Jan;17(1):85–103. doi: 10.1016/0090-8258(84)90063-5. [DOI] [PubMed] [Google Scholar]
  3. Aalders J. G., Abeler V., Kolstad P. Stage IV endometrial carcinoma: a clinical and histopathological study of 83 patients. Gynecol Oncol. 1984 Jan;17(1):75–84. doi: 10.1016/0090-8258(84)90062-3. [DOI] [PubMed] [Google Scholar]
  4. Abayomi O., Dritschilo A., Emami B., Watring W. G., Piro A. J. The value of "routine tests" in the staging evaluation of gynecologic malignancies: a cost effectiveness analysis. Int J Radiat Oncol Biol Phys. 1982 Feb;8(2):241–244. doi: 10.1016/0360-3016(82)90520-x. [DOI] [PubMed] [Google Scholar]
  5. An-Foraker S. H., Kawada C. Y., McKinney D. Endometrial aspiration studies on Isaacs cell sampler with cytohistologic correlation. Acta Cytol. 1979 Jul-Aug;23(4):303–308. [PubMed] [Google Scholar]
  6. Anderson B., Louis F., Watring W. G., Edinger D. D., Jr Growth patterns in endometrial carcinoma. Gynecol Oncol. 1980 Oct;10(2):134–145. doi: 10.1016/0090-8258(80)90075-x. [DOI] [PubMed] [Google Scholar]
  7. Anderson B., Marchant D. J., Munzenrider J. E., Moore J. P., Mitchell G. W., Jr Routine noninvasive hysterography in the evaluation and treatment of endometrial carcinoma. Gynecol Oncol. 1976 Dec;4(4):354–367. doi: 10.1016/0090-8258(76)90045-7. [DOI] [PubMed] [Google Scholar]
  8. Ballon S. C., Berman M. L., Donaldson R. C., Growdon W. A., Lagasse L. D. Pulmonary metastases of endometrial carcinoma. Gynecol Oncol. 1979 Feb;7(1):56–65. doi: 10.1016/0090-8258(79)90081-7. [DOI] [PubMed] [Google Scholar]
  9. Bean H. A., Bryant A. J., Carmichael J. A., Mallik A. Carcinoma of the endometrium in Saskatchewan: 1966 to 1971. Gynecol Oncol. 1978 Dec;6(6):503–514. doi: 10.1016/0090-8258(78)90062-8. [DOI] [PubMed] [Google Scholar]
  10. Bergeron C., Ferenczy A., Shyamala G. Distribution of estrogen receptors in various cell types of normal, hyperplastic, and neoplastic human endometrial tissues. Lab Invest. 1988 Mar;58(3):338–345. [PubMed] [Google Scholar]
  11. Berman M. L., Afridi M. A., Kanbour A. I., Ball H. G. Risk factors and prognosis in stage II endometrial cancer. Gynecol Oncol. 1982 Aug;14(1):49–61. doi: 10.1016/0090-8258(82)90050-6. [DOI] [PubMed] [Google Scholar]
  12. Bigelow B., Vekshtein V., Demopoulos R. I. Endometrial carcinoma, stage II: route and extent of spread to the cervix. Obstet Gynecol. 1983 Sep;62(3):363–366. [PubMed] [Google Scholar]
  13. Bokhman J. V. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983 Feb;15(1):10–17. doi: 10.1016/0090-8258(83)90111-7. [DOI] [PubMed] [Google Scholar]
  14. Bonte J., Ide P., Billiet G., Wynants P. Tamoxifen as a possible chemotherapeutic agent in endometrial adenocarcinoma. Gynecol Oncol. 1981 Apr;11(2):140–161. doi: 10.1016/s0090-8258(81)80003-0. [DOI] [PubMed] [Google Scholar]
  15. Boronow R. C., Morrow C. P., Creasman W. T., Disaia P. J., Silverberg S. G., Miller A., Blessing J. A. Surgical staging in endometrial cancer: clinical-pathologic findings of a prospective study. Obstet Gynecol. 1984 Jun;63(6):825–832. [PubMed] [Google Scholar]
  16. Bruckman J. E., Bloomer W. D., Marck A., Ehrmann R. L., Knapp R. C. Stage III adenocarcinoma of the endometrium: two prognostic groups. Gynecol Oncol. 1980 Feb;9(1):12–17. doi: 10.1016/0090-8258(80)90003-7. [DOI] [PubMed] [Google Scholar]
  17. Bruckman J. E., Goodman R. L., Murthy A., Marck A. Combined irradiation and surgery in the treatment of stage II carcinoma of the endometrium. Cancer. 1978 Sep;42(3):1146–1151. doi: 10.1002/1097-0142(197809)42:3<1146::aid-cncr2820420318>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  18. Budwit-Novotny D. A., McCarty K. S., Cox E. B., Soper J. T., Mutch D. G., Creasman W. T., Flowers J. L., McCarty K. S., Jr Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer Res. 1986 Oct;46(10):5419–5425. [PubMed] [Google Scholar]
  19. Chambers J. T. Sex steroid receptors in endometrial cancer. Yale J Biol Med. 1988 Jul-Aug;61(4):339–350. [PMC free article] [PubMed] [Google Scholar]
  20. Chauvergne J., Granger C., Mage P., Pigneux J., David M. Chimiothérapie palliative des cancers de l'endomètre. Intérêt d'associations avec doxorubicine et cisplatine. Rev Fr Gynecol Obstet. 1986 Oct;81(10):547–551. [PubMed] [Google Scholar]
  21. Cheng L., Binder S. W., Fu Y. S., Lewin K. J. Demonstration of estrogen receptors by monoclonal antibody in formalin-fixed breast tumors. Lab Invest. 1988 Mar;58(3):346–353. [PubMed] [Google Scholar]
  22. Christopherson W. M., Alberhasky R. C., Connelly P. J. Carcinoma of the endometrium. II. Papillary adenocarcinoma: a clinical pathological study, 46 cases. Am J Clin Pathol. 1982 May;77(5):534–540. doi: 10.1093/ajcp/77.5.534. [DOI] [PubMed] [Google Scholar]
  23. Christopherson W. M., Alberhasky R. C., Connelly P. J. Carcinoma of the endometrium: I. A clinicopathologic study of clear-cell carcinoma and secretory carcinoma. Cancer. 1982 Apr 15;49(8):1511–1523. doi: 10.1002/1097-0142(19820415)49:8<1511::aid-cncr2820490802>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  24. Christopherson W. M., Connelly P. J., Alberhasky R. C. Carcinoma of the endometrium. V. An analysis of prognosticators in patients with favorable subtypes and Stage I disease. Cancer. 1983 May 1;51(9):1705–1709. doi: 10.1002/1097-0142(19830501)51:9<1705::aid-cncr2820510924>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  25. Cohen C. J. Cytotoxic chemotherapy for patients with endometrial carcinoma. Clin Obstet Gynaecol. 1986 Dec;13(4):811–824. [PubMed] [Google Scholar]
  26. Cowles T. A., Magrina J. F., Masterson B. J., Capen C. V. Comparison of clinical and surgical-staging in patients with endometrial carcinoma. Obstet Gynecol. 1985 Sep;66(3):413–416. [PubMed] [Google Scholar]
  27. Creasman W. T., Soper J. T., McCarty K. S., Jr, McCarty K. S., Sr, Hinshaw W., Clarke-Pearson D. L. Influence of cytoplasmic steroid receptor content on prognosis of early stage endometrial carcinoma. Am J Obstet Gynecol. 1985 Apr 1;151(7):922–932. doi: 10.1016/0002-9378(85)90671-4. [DOI] [PubMed] [Google Scholar]
  28. Crissman J. D., Azoury R. S., Barnes A. E., Schellhas H. F. Endometrial carcinoma in women 40 years of age or younger. Obstet Gynecol. 1981 Jun;57(6):699–704. [PubMed] [Google Scholar]
  29. Deligdisch L., Cohen C. J. Histologic correlates and virulence implications of endometrial carcinoma associated with adenomatous hyperplasia. Cancer. 1985 Sep 15;56(6):1452–1455. doi: 10.1002/1097-0142(19850915)56:6<1452::aid-cncr2820560637>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  30. Deppe G., Malviya V. K., Zbella E. Nonhormonal chemotherapy in endometrial cancer--a review. Wien Klin Wochenschr. 1984 Oct 26;96(20):747–756. [PubMed] [Google Scholar]
  31. Devesa S. S., Silverman D. T., Young J. L., Jr, Pollack E. S., Brown C. C., Horm J. W., Percy C. L., Myers M. H., McKay F. W., Fraumeni J. F., Jr Cancer incidence and mortality trends among whites in the United States, 1947-84. J Natl Cancer Inst. 1987 Oct;79(4):701–770. [PubMed] [Google Scholar]
  32. DiSaia P. J., Creasman W. T., Boronow R. C., Blessing J. A. Risk factors and recurrent patterns in Stage I endometrial cancer. Am J Obstet Gynecol. 1985 Apr 15;151(8):1009–1015. doi: 10.1016/0002-9378(85)90371-0. [DOI] [PubMed] [Google Scholar]
  33. Ehrlich C. E., Young P. C., Cleary R. E. Cytoplasmic progesterone and estradiol receptors in normal, hyperplastic, and carcinomatous endometria: therapeutic implications. Am J Obstet Gynecol. 1981 Nov 1;141(5):539–546. doi: 10.1016/s0002-9378(15)33275-0. [DOI] [PubMed] [Google Scholar]
  34. Ehrlich C. E., Young P. C., Stehman F. B., Sutton G. P., Alford W. M. Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium. Am J Obstet Gynecol. 1988 Apr;158(4):796–807. doi: 10.1016/0002-9378(88)90075-0. [DOI] [PubMed] [Google Scholar]
  35. Ferenczy A., Gelfand M. M. Outpatient endometrial sampling with Endocyte: comparative study of its effectiveness with endometrial biopsy. Obstet Gynecol. 1984 Mar;63(3):295–302. [PubMed] [Google Scholar]
  36. Fu Y. S., Ferenczy A., Huang I., Gelfand M. M. Digital imaging analysis of normal, hyperplastic and malignant endometrial cells in endometrial brushing samples. Anal Quant Cytol Histol. 1988 Apr;10(2):139–149. [PubMed] [Google Scholar]
  37. GREENE J. W., Jr Feminizing mesenchymomas (granulosa-cell and theca-cell tumors) with associated endometrial carcinoma; review of the literature, and a study of the material of the ovarian tumor registry. Am J Obstet Gynecol. 1957 Jul;74(1):31–41. doi: 10.1016/s0002-9378(16)37000-4. [DOI] [PubMed] [Google Scholar]
  38. Gallup D. G., Stock R. J. Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstet Gynecol. 1984 Sep;64(3):417–420. [PubMed] [Google Scholar]
  39. Gambone J. C., Pardridge W. M., Lagasse L. D., Judd H. L. In vivo availability of circulating estradiol in postmenopausal women with and without endometrial cancer. Obstet Gynecol. 1982 Apr;59(4):416–421. [PubMed] [Google Scholar]
  40. Geisinger K. R., Homesley H. D., Morgan T. M., Kute T. E., Marshall R. B. Endometrial adenocarcinoma. A multiparameter clinicopathologic analysis including the DNA profile and the sex steroid hormone receptors. Cancer. 1986 Oct 1;58(7):1518–1525. doi: 10.1002/1097-0142(19861001)58:7<1518::aid-cncr2820580723>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  41. Genest P., Drouin P., Girard A., Gerig L. Stage III carcinoma of the endometrium: a review of 41 cases. Gynecol Oncol. 1987 Jan;26(1):77–86. doi: 10.1016/0090-8258(87)90073-4. [DOI] [PubMed] [Google Scholar]
  42. Goplerud D. R., Belgrad R. The importance of histologic grade in stage II endometrial carcinoma. Surg Gynecol Obstet. 1979 Mar;148(3):406–408. [PubMed] [Google Scholar]
  43. Greene G. L., Fitch F. W., Jensen E. V. Monoclonal antibodies to estrophilin: probes for the study of estrogen receptors. Proc Natl Acad Sci U S A. 1980 Jan;77(1):157–161. doi: 10.1073/pnas.77.1.157. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Greer B. E., Hamberger A. D. Treatment of intraperitoneal metastatic adenocarcinoma of the endometrium by the whole-abdomen moving-strip technique and pelvic boost irradiation. Gynecol Oncol. 1983 Dec;16(3):365–373. doi: 10.1016/0090-8258(83)90164-6. [DOI] [PubMed] [Google Scholar]
  45. Grigsby P. W., Perez C. A., Camel H. M., Kao M. S., Galakatos A. E. Stage II carcinoma of the endometrium: results of therapy and prognostic factors. Int J Radiat Oncol Biol Phys. 1985 Nov;11(11):1915–1923. doi: 10.1016/0360-3016(85)90272-x. [DOI] [PubMed] [Google Scholar]
  46. Gusberg S. B., Milano C. Detection of endometrial cancer and its precursors. Cancer. 1981 Mar 1;47(5 Suppl):1173–1175. doi: 10.1002/1097-0142(19810301)47:5+<1173::aid-cncr2820471320>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  47. Hall T. L., Fu Y. S. Applications of quantitative microscopy in tumor pathology. Lab Invest. 1985 Jul;53(1):5–21. [PubMed] [Google Scholar]
  48. Hammond C. B., Jelovsek F. R., Lee K. L., Creasman W. T., Parker R. T. Effects of long-term estrogen replacement therapy. II. Neoplasia. Am J Obstet Gynecol. 1979 Mar 1;133(5):537–547. doi: 10.1016/0002-9378(79)90289-8. [DOI] [PubMed] [Google Scholar]
  49. Harouny V. R., Sutton G. P., Clark S. A., Geisler H. E., Stehman F. B., Ehrlich C. E. The importance of peritoneal cytology in endometrial carcinoma. Obstet Gynecol. 1988 Sep;72(3 Pt 1):394–398. [PubMed] [Google Scholar]
  50. Henderson B. E., Ross R., Bernstein L. Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation award lecture. Cancer Res. 1988 Jan 15;48(2):246–253. [PubMed] [Google Scholar]
  51. Hendrickson M., Ross J., Eifel P., Martinez A., Kempson R. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol. 1982 Mar;6(2):93–108. doi: 10.1097/00000478-198203000-00002. [DOI] [PubMed] [Google Scholar]
  52. Hernandez W., Nolan J. F., Morrow C. P., Jernstrom P. H. Stage II endometrial carcinoma: two modalities of treatment. Am J Obstet Gynecol. 1978 May 15;131(2):171–175. doi: 10.1016/0002-9378(78)90660-9. [DOI] [PubMed] [Google Scholar]
  53. Heyns W., De Moor P. The binding of 17 -hydroxy-5 -androstan-3-one to the steroid-binding -globulin in human plasma, as studied by means of ammonium sulphate precipitation. Steroids. 1971 Dec;18(6):709–730. doi: 10.1016/0039-128x(71)90031-6. [DOI] [PubMed] [Google Scholar]
  54. Hricak H., Stern J. L., Fisher M. R., Shapeero L. G., Winkler M. L., Lacey C. G. Endometrial carcinoma staging by MR imaging. Radiology. 1987 Feb;162(2):297–305. doi: 10.1148/radiology.162.2.3797641. [DOI] [PubMed] [Google Scholar]
  55. Hørding U., Hansen U. Stage I endometrial carcinoma: a review of 140 patients primarily treated by surgery only. Gynecol Oncol. 1985 Sep;22(1):51–58. doi: 10.1016/0090-8258(85)90007-1. [DOI] [PubMed] [Google Scholar]
  56. Iversen O. E. Flow cytometric deoxyribonucleic acid index: a prognostic factor in endometrial carcinoma. Am J Obstet Gynecol. 1986 Oct;155(4):770–776. doi: 10.1016/s0002-9378(86)80018-7. [DOI] [PubMed] [Google Scholar]
  57. Judd H. L., Davidson B. J., Frumar A. M., Shamonki I. M., Lagasse L. D., Ballon S. C. Serum androgens and estrogens in postmenopausal women with and without endometrial cancer. Am J Obstet Gynecol. 1980 Apr 1;136(7):859–871. doi: 10.1016/0002-9378(80)91043-1. [DOI] [PubMed] [Google Scholar]
  58. KELLEY R. M., BAKER W. H. Progestational agents in the treatment of carcinoma of the endometrium. N Engl J Med. 1961 Feb 2;264:216–222. doi: 10.1056/NEJM196102022640503. [DOI] [PubMed] [Google Scholar]
  59. Kadar N. R., Kohorn E. I., LiVolsi V. A., Kapp D. S. Histologic variants of cervical involvement by endometrial carcinoma. Obstet Gynecol. 1982 Jan;59(1):85–92. [PubMed] [Google Scholar]
  60. Kinsella T. J., Bloomer W. D., Lavin P. T., Knapp R. C. Stage II endometrial carcinoma: 10-year follow-up of combined radiation and surgical treatment. Gynecol Oncol. 1980 Dec;10(3):290–297. doi: 10.1016/0090-8258(80)90096-7. [DOI] [PubMed] [Google Scholar]
  61. Kneale B. L. Adjunctive and therapeutic progestins in endometrial cancer. Clin Obstet Gynaecol. 1986 Dec;13(4):789–809. [PubMed] [Google Scholar]
  62. Kohorn E. I. Gestagens and endometrial carcinoma. Gynecol Oncol. 1976 Dec;4(4):398–411. doi: 10.1016/0090-8258(76)90050-0. [DOI] [PubMed] [Google Scholar]
  63. Komaki R., Cox J. D., Hartz A., Wilson J. F., Greenberg M. Influence of preoperative irradiation on failures of endometrial carcinoma with high risk of lymph node metastasis. Am J Clin Oncol. 1984 Dec;7(6):661–668. doi: 10.1097/00000421-198412000-00013. [DOI] [PubMed] [Google Scholar]
  64. Koss L. G., Schreiber K., Oberlander S. G., Moussouris H. F., Lesser M. Detection of endometrial carcinoma and hyperplasia in asymptomatic women. Obstet Gynecol. 1984 Jul;64(1):1–11. [PubMed] [Google Scholar]
  65. Kurman R. J., Kaminski P. F., Norris H. J. The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients. Cancer. 1985 Jul 15;56(2):403–412. doi: 10.1002/1097-0142(19850715)56:2<403::aid-cncr2820560233>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  66. Lewis G. C., Jr, Slack N. H., Mortel R., Bross I. D. Adjuvant progestogen therapy in the primary definitive treatment of endometrial cancer. Gynecol Oncol. 1974 Aug;2(2-3):368–376. doi: 10.1016/0090-8258(74)90028-6. [DOI] [PubMed] [Google Scholar]
  67. Lotocki R. J., Copeland L. J., DePetrillo A. D., Muirhead W. Stage I endometrial adenocarcinoma: treatment results in 835 patients. Am J Obstet Gynecol. 1983 May 15;146(2):141–145. doi: 10.1016/0002-9378(83)91042-6. [DOI] [PubMed] [Google Scholar]
  68. Lozowski M. S., Mishriki Y., Solitare G. B. Factors determining the degree of endometrial exfoliation and their diagnostic implications in endometrial adenocarcinoma. Acta Cytol. 1986 Nov-Dec;30(6):623–627. [PubMed] [Google Scholar]
  69. MANSELL H., HERTIG A. T. Granulosatheca cell tumors and endometrial carcinoma; a study of their relationship and a survey of 80 cases. Obstet Gynecol. 1955 Oct;6(4):385–394. [PubMed] [Google Scholar]
  70. MEISSNER W. A., SOMMERS S. C., SHERMAN G. Endometrial hyperplasia, endometrial carcinoma, and endometriosis produced experimentally by estrogen. Cancer. 1957 May-Jun;10(3):500–509. doi: 10.1002/1097-0142(195705/06)10:3<500::aid-cncr2820100312>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  71. MacDonald P. C., Edman C. D., Hemsell D. L., Porter J. C., Siiteri P. K. Effect of obesity on conversion of plasma androstenedione to estrone in postmenopausal women with and without endometrial cancer. Am J Obstet Gynecol. 1978 Feb 15;130(4):448–455. doi: 10.1016/0002-9378(78)90287-9. [DOI] [PubMed] [Google Scholar]
  72. Mackillop W. J., Pringle J. F. Stage III endometrial carcinoma. A review of 90 cases. Cancer. 1985 Nov 15;56(10):2519–2523. doi: 10.1002/1097-0142(19851115)56:10<2519::aid-cncr2820561033>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  73. Malkasian G. D., Jr, McDonald T. W., Pratt J. H. Carcinoma of the endometrium: Mayo clinic experience. Mayo Clin Proc. 1977 Mar;52(3):175–180. [PubMed] [Google Scholar]
  74. Martin P. M., Rolland P. H., Gammerre M., Serment H., Toga M. Estradiol and progesterone receptors in normal and neoplastic endometrium: correlations between receptors, histopathological examinations and clinical responses under progestin therapy. Int J Cancer. 1979 Mar 15;23(3):321–329. doi: 10.1002/ijc.2910230309. [DOI] [PubMed] [Google Scholar]
  75. McCarty K. S., Jr, Barton T. K., Fetter B. F., Creasman W. T., McCarty K. S., Sr Correlation of estrogen and progesterone receptors with histologic differentiation in endometrial adenocarcinoma. Am J Pathol. 1979 Jul;96(1):171–183. [PMC free article] [PubMed] [Google Scholar]
  76. Morrow C. P., Di Saia P. J., Townsend D. E. Current management of endometrial carcinoma. Obstet Gynecol. 1973 Sep;42(3):399–406. [PubMed] [Google Scholar]
  77. Musumeci R., De Palo G., Conti U., Kenda R., Mangioni C., Belloni C., Marzi M., Bandieramonte G. Are retroperitoneal lymph node metastases a major problem in endometrial adenocarcinoma? Diagnostic and prognostic assessment with lymphography. Cancer. 1980 Oct 15;46(8):1887–1892. doi: 10.1002/1097-0142(19801015)46:8<1887::aid-cncr2820460831>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  78. Nahhas W. A., Whitney C. W., Stryker J. A., Curry S. L., Chung C. K., Mortel R. Stage II endometrial carcinoma. Gynecol Oncol. 1980 Dec;10(3):303–311. doi: 10.1016/0090-8258(80)90098-0. [DOI] [PubMed] [Google Scholar]
  79. Nemoto T., Patel J., Rosner D., Dao T. L. Oral medroxyprogesterone in the treatment of metastatic breast cancer. J Surg Oncol. 1986 Aug;32(4):211–213. doi: 10.1002/jso.2930320406. [DOI] [PubMed] [Google Scholar]
  80. Onsrud M., Aalders J., Abeler V., Taylor P. Endometrial carcinoma with cervical involvement (stage II): prognostic factors and value of combined radiological-surgical treatment. Gynecol Oncol. 1982 Feb;13(1):76–86. doi: 10.1016/0090-8258(82)90011-7. [DOI] [PubMed] [Google Scholar]
  81. Onsrud M., Kolstad P., Normann T. Postoperative external pelvic irradiation in carcinoma of the corpus stage I: a controlled clinical trial. Gynecol Oncol. 1976 Jun;4(2):222–231. doi: 10.1016/0090-8258(76)90064-0. [DOI] [PubMed] [Google Scholar]
  82. Palermo V. G., Blythe J. G., Kaufman R. H. Cytologic diagnosis of endometrial adenocarcinoma using the Endo-pap sampler. Obstet Gynecol. 1985 Feb;65(2):271–275. [PubMed] [Google Scholar]
  83. Pasmantier M. W., Coleman M., Silver R. T., Mamaril A. P., Quiguyan C. C., Galindo A., Jr Treatment of advanced endometrial carcinoma with doxorubicin and cisplatin: effects on both untreated and previously treated patients. Cancer Treat Rep. 1985 May;69(5):539–542. [PubMed] [Google Scholar]
  84. Peters W. A., 3rd, Andersen W. A., Thornton W. N., Jr, Morley G. W. The selective use of vaginal hysterectomy in the management of adenocarcinoma of the endometrium. Am J Obstet Gynecol. 1983 Jun 1;146(3):285–289. doi: 10.1016/0002-9378(83)90750-0. [DOI] [PubMed] [Google Scholar]
  85. Phillips G. L., Prem K. A., Adcock L. L., Twiggs L. B. Vaginal recurrence of adenocarcinoma of the endometrium. Gynecol Oncol. 1982 Jun;13(3):323–328. doi: 10.1016/0090-8258(82)90070-1. [DOI] [PubMed] [Google Scholar]
  86. Piver M. S., Yazigi R., Blumenson L., Tsukada Y. A prospective trail comparing hysterectomy, hysterectomy plus vaginal radium, and uterine radium plus hysterectomy in stage I endometrial carcinoma. Obstet Gynecol. 1979 Jul;54(1):85–89. doi: 10.1097/00006250-197907000-00020. [DOI] [PubMed] [Google Scholar]
  87. Potish R. A., Twiggs L. B., Adcock L. L., Prem K. A. Role of whole abdominal radiation therapy in the management of endometrial cancer; prognostic importance of factors indicating peritoneal metastases. Gynecol Oncol. 1985 May;21(1):80–86. doi: 10.1016/0090-8258(85)90235-5. [DOI] [PubMed] [Google Scholar]
  88. Potish R. A., Twiggs L. B., Adcock L. L., Savage J. E., Levitt S. H., Prem K. A. Paraaortic lymph node radiotherapy in cancer of the uterine corpus. Obstet Gynecol. 1985 Feb;65(2):251–256. [PubMed] [Google Scholar]
  89. Ritcher N., Lucas W. E., Yon J. L., Jr, Sanford F. G. Preoperative whole pelvic external irradiation in stage I endometrial cancer. Cancer. 1981 Jul 1;48(1):58–62. doi: 10.1002/1097-0142(19810701)48:1<58::aid-cncr2820480113>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  90. Robboy S. J., Miller A. W., 3rd, Kurman R. J. The pathologic features and behavior of endometrial carcinoma associated with exogenous estrogen administration. Pathol Res Pract. 1982 Aug;174(3):237–256. doi: 10.1016/S0344-0338(82)80069-1. [DOI] [PubMed] [Google Scholar]
  91. Rutledge F. The role of radical hysterectomy in adenocarcinoma of the endometrium. Gynecol Oncol. 1974 Aug;2(2-3):331–347. doi: 10.1016/0090-8258(74)90024-9. [DOI] [PubMed] [Google Scholar]
  92. Salazar O. M., Feldstein M. L., DePapp E. W., Bonfiglio T. A., Keller B. E., Rubin P., Rudolph J. H. Endometrial carcinoma: analysis of failures with special emphasis on the use of initial preoperative external pelvic radiation. Int J Radiat Oncol Biol Phys. 1977 Nov-Dec;2(11-12):1101–1107. doi: 10.1016/0360-3016(77)90116-x. [DOI] [PubMed] [Google Scholar]
  93. Schneider M. L., Wortmann M., Weigel A. Influence of the histologic and cytologic grade and the clinical and postsurgical stage on the rate of endometrial carcinoma detection by cervical cytology. Acta Cytol. 1986 Nov-Dec;30(6):616–622. [PubMed] [Google Scholar]
  94. Seltzer V., Vogl S. E., Kaplan B. H. Adriamycin and cis-diamminedichloroplatinum in the treatment of metastatic endometrial adenocarcinoma. Gynecol Oncol. 1984 Nov;19(3):308–313. doi: 10.1016/0090-8258(84)90197-5. [DOI] [PubMed] [Google Scholar]
  95. Seski J. C., Edwards C. L., Herson J., Rutledge F. N. Cisplatin chemotherapy for disseminated endometrial cancer. Obstet Gynecol. 1982 Feb;59(2):225–228. [PubMed] [Google Scholar]
  96. Silverberg E., Lubera J. A. Cancer statistics, 1989. CA Cancer J Clin. 1989 Jan-Feb;39(1):3–20. doi: 10.3322/canjclin.39.1.3. [DOI] [PubMed] [Google Scholar]
  97. Silverberg S. G., Mullen D., Faraci J. A., Makowski E. L., Miller A., Finch J. L., Sutherland J. V. Endometrial carcinoma: clinical-pathologic comparison of cases in postmenopausal women receiving and not receiving exogenous estrogens. Cancer. 1980 Jun 15;45(12):3018–3026. doi: 10.1002/1097-0142(19800615)45:12<3018::aid-cncr2820451224>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  98. Soper J. T., Creasman W. T., Clarke-Pearson D. L., Sullivan D. C., Vergadoro F., Johnston W. W. Intraperitoneal chromic phosphate P 32 suspension therapy of malignant peritoneal cytology in endometrial carcinoma. Am J Obstet Gynecol. 1985 Sep 15;153(2):191–196. doi: 10.1016/0002-9378(85)90112-7. [DOI] [PubMed] [Google Scholar]
  99. Stelmachów J. The role of hysteroscopy in gynecologic oncology. Gynecol Oncol. 1982 Dec;14(3):392–395. doi: 10.1016/0090-8258(82)90114-7. [DOI] [PubMed] [Google Scholar]
  100. Stokes S., Bedwinek J., Breaux S., Kao M. S., Camel M., Perez C. A. Treatment of stage I adenocarcinoma of the endometrium by hysterectomy and irradiation: analysis of complications. Obstet Gynecol. 1985 Jan;65(1):86–92. [PubMed] [Google Scholar]
  101. Surwit E. A., Joelsson I., Einhorn N. Adjunctive radiation therapy in the management of stage I cancer of the endometrium. Obstet Gynecol. 1981 Nov;58(5):590–595. [PubMed] [Google Scholar]
  102. Swenerton K. D. Treatment of advanced endometrial adenocarcinoma with tamoxifen. Cancer Treat Rep. 1980 Jun-Jul;64(6-7):805–811. [PubMed] [Google Scholar]
  103. Tak W. K. Carcinoma of the endometrium with cervical involvement (state II). Cancer. 1979 Jun;43(6):2504–2504. doi: 10.1002/1097-0142(197906)43:6<2504::aid-cncr2820430650>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  104. Thigpen J. T., Buchsbaum H. J., Mangan C., Blessing J. A. Phase II trial of adriamycin in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Cancer Treat Rep. 1979 Jan;63(1):21–27. [PubMed] [Google Scholar]
  105. Tiitinen A., Forss M., Aho I., Vesterinen E., Nieminen U. Endometrial adenocarcinoma: clinical outcome in 881 patients and analysis of 146 patients whose deaths were due to endometrial cancer. Gynecol Oncol. 1986 Sep;25(1):11–19. doi: 10.1016/0090-8258(86)90059-4. [DOI] [PubMed] [Google Scholar]
  106. Wallin T. E., Malkasian G. D., Jr, Gaffey T. A., O'Brien P. C., Fountain K. S. Stage II cancer of the endometrium: a pathologic and clinical study. Gynecol Oncol. 1984 May;18(1):1–17. doi: 10.1016/0090-8258(84)90001-5. [DOI] [PubMed] [Google Scholar]
  107. Weiss N. S., Szekely D. R., Austin D. F. Increasing incidence of endometrial cancer in the United States. N Engl J Med. 1976 Jun 3;294(23):1259–1262. doi: 10.1056/NEJM197606032942303. [DOI] [PubMed] [Google Scholar]
  108. Zaino R. J., Clarke C. L., Mortel R., Satyaswaroop P. G. Heterogeneity of progesterone receptor distribution in human endometrial adenocarcinoma. Cancer Res. 1988 Apr 1;48(7):1889–1895. [PubMed] [Google Scholar]

Articles from Western Journal of Medicine are provided here courtesy of BMJ Publishing Group

RESOURCES